fbpx

Our Team

Our staff come from well-known local and overseas universities. With the latest knowledge of life science technology, we are building a trustworthy molecular testing organization.

Teamwork—Each of our staff has extensive professional knowledge. To achieve the best work efficiency, we put the team collaboration at the highest priority, enabling our the service to achieve a higher level.


Top scientific research team

Our top scientific research team is comprised of more than 70 experts, including over 20 PhD holders and licensed genetic counsellors to provide genetic consulting service towards public.

DR. DAVID HO

Dr. Ho earned his Laboratory Medical Sciences degree from the University of British Columbia in Canada, followed by an MPhil and a PhD from the University of Hong Kong. Prior to his current role at Pangenia, Dr. Ho spent many years at the University of Hong Kong, where he focused on cancer research and laboratory management. His extensive research has been published in several esteemed journals including Cancer Cell, Hepatology, Cancer, and Gut. Currently, he serves as the Laboratory Director at Pangenia Lifesciences Ltd.

DR. TYLER LEUNG

Dr. Tyler Leung possesses over 16 years of cross-domain experience since earning his Ph.D in Biotechnology. He has held positions in the private sector, government-supported research and development centers such as NAMI and ASTRI, and universities, focusing on business engagement, technology translation, product development, and corporate-level project management.

Dr. Leung currently serves as Assistant General Manager at DiagCor Life Science Limited, a Hong Kong-based molecular diagnostics (MDx) company established in 2006. The company specializes in developing and manufacturing IVD products and holds ISO 13485 certification and CE-IVD registration for international markets. Additionally, he supports Pangenia Lifescience as a panel member of women and men health molecular diagnostics division to promote a healthier society by researching, developing and commercializing MDx innovations.